title: Formulation and in vitro evaluation of bilayer tablets of nebivolol hydrochloride and nateglinide for the treatment of diabetes and hypertension.
abstract: Diabetes mellitus (DM) and hypertension are two common diseases that often coexist. The most common cause of death in the diabetic patient is heart disease. In the present investigation we combine Nebivolol and Nateglinide for better patient compliance. IR layer was formulated using various superdisintegrants like Crospovidone, Croscarmellose sodium, and sodium starch glycolate and SR layer was formulated using polymers and gums like HPMC E15, ethyl cellulose, Gaur gum, and Xanthan gum. The disintegration and dissolution study of both layers showed that inclusion of surfactant (sodium lauryl sulphate) to the tablet formulation (IR) and dissolution medium (SR) enhanced the release of drugs from both layers. Kinetic studies of optimized IR layer (NBL8) and SR layer (N9) showed good linearity with regression coefficient of 0.9714 (Higuchi model) and 0.9931 (zero order kinetics), respectively. The above results reveal that the optimized IR layer of Nebivolol (NBL8) and SR layer of Nateglinide (N9) might be suitable for the treatment of diabetes and hypertension by sequential release of the two drugs in a bilayer tablet. IR-immediate release, SR-sustain release, NBL8-Nebivolol 8, N9-Nateglinide 9.
authors: Vishnu Institute of Pharmaceutical Education and Research, Vishnupur, Narsapur, Medak, Telangana 502313, India.
authors: Harika
authors: H
authors: Ryakala
authors: Vishnu Institute of Pharmaceutical Education and Research, Vishnupur, Narsapur, Medak, Telangana 502313, India.
authors: S
authors: S
authors: Dineshmohan
authors: Vishnu Institute of Pharmaceutical Education and Research, Vishnupur, Narsapur, Medak, Telangana 502313, India.
authors: Alluri
authors: A
authors: Ramesh
authors: Department of Pharmaceutics, Pulla Reddy Institute of Pharmacy, Annaram, Hyderabad 502313, India.
authors: V R M
authors: VR
authors: Gupta
references: Ann Pharmacother. 2006 Jul-Aug;40(7-8):1353-60
references: 16822893
references: Hypertension. 1992 May;19(5):403-18
references: 1568757
references: Expert Opin Pharmacother. 2007 Jul;8(10):1539-50
references: 17661735
references: Drugs. 2000 Sep;60(3):607-615; discussion 616-7
references: 11030470
references: Am J Cardiol. 2003 Aug 1;92 (3):344-8
references: 12888152
references: Diabetes Res Clin Pract. 2008 Nov;82(2):276-81
references: 18814927
references: Drugs Today (Barc). 2001 Jun;37(6):411-426
references: 12764427
references: J Cardiovasc Pharmacol. 2001 Dec;38 Suppl 3:S33-5
references: 11811391